Myeloproliferative Neoplasm | Norton Healthcare

Indication: Myeloproliferative Neoplasm

A Phase 1 Open-Label Study Evaluating the Safety and Tolerability, and Pharmacokinetics of Navitoclax Monotherapy and in Combination with Ruxolitinib in Myeloproliferative Neoplasm Subjects

Sub-indication: Hematological Malignancies

Study Type: Drug Study

Principal Investigator: Don Stevens, M.D.
Norton Cancer Institute

Sponsor: Sponsor: AbbVie

Search our entire site.

Schedule an Appointment

Select an appointment date and time from available spots listed below.